Meeting News Coverage

CRISP AMI: Intra-aortic balloon pump counterpulsation failed to reduce infarct size in STEMI patients

European Society of Cardiology Congress 2011

Infarct size as measured by MRI does not reduce when intra-aortic balloon pump counterpulsation is used before percutaneous coronary intervention in patients with STEMI, new study results indicated.

In the CRISP AMI trial, patients with acute STEMI without shock were randomly assigned into two groups. One group included 161 patients who received intra-aortic balloon counterpulsation (IABC), and the second group included 176 patients who received primary PCI without IABC support (SOC). Patients included had chest pain onset within 6 hours and planned primary PCI. Researchers had an infarct size measured by cardiac MRI at 3 to 5 days post-PCI as the primary efficacy endpoint, and a secondary clinical endpoint was a composite of major adverse clinical events that included death, reinfarction and HF at 6 months. Results of the trial were presented at the European Society of Cardiology Congress 2011 in Paris.

“Animal studies had suggested that inserting a balloon pump before opening the vessel would reduce the heart’s workload and, by doing so, could potentially reduce size,” Manesh Patel, MD, of the Duke Clinical Research Institute at Duke University, said in a press release. “However, having tested this observation in humans, we did not show similar results.”

IABC and SOC groups did not have significantly different mean infarct sizes. The percentage of left ventricle affected in the IABC group was 42.1% vs. 37.5% in the SOC group. Major bleeding or transfusion occurred in 3.1% of IABC patients and 1.7% of SOC patients by 30 days, and major vascular complications occurred in 4.3% of IABC patients and 1.1% of SOC patients. Death occurred by 6 months in 1.9% of IABC patients and 5.2% of SOC patients. Overall, not only did the study no meet its primary endpoint, it was also not powered to draw significant conclusions on clinical events.

“While this trial shows that the routine use of IABC cannot be recommended in STEMI, physicians should be vigilant about identifying those patients who are at risk for rapid deterioration and may benefit from counterpulsation,” Patel said.

For more information:

Disclosure: Dr. Patel reports no relevant financial disclosures.

PERSPECTIVE

Potential benefits of IABC are increase of coronary blood flow, increase of diastolic BP, increase of collateral circulation, increase of organ perfusion, decrease of afterload and increase of CI. [However,] IABC is not for all-comers with STEMI, and patients who might benefit from IABP still have to be defined.

Kurt Huber, MD
Department of Medicine, Cardiology and Emergency Medicine
Wilhelminen Hospital, Austria

Twitter Follow CardiologyToday.com on Twitter.

European Society of Cardiology Congress 2011

Infarct size as measured by MRI does not reduce when intra-aortic balloon pump counterpulsation is used before percutaneous coronary intervention in patients with STEMI, new study results indicated.

In the CRISP AMI trial, patients with acute STEMI without shock were randomly assigned into two groups. One group included 161 patients who received intra-aortic balloon counterpulsation (IABC), and the second group included 176 patients who received primary PCI without IABC support (SOC). Patients included had chest pain onset within 6 hours and planned primary PCI. Researchers had an infarct size measured by cardiac MRI at 3 to 5 days post-PCI as the primary efficacy endpoint, and a secondary clinical endpoint was a composite of major adverse clinical events that included death, reinfarction and HF at 6 months. Results of the trial were presented at the European Society of Cardiology Congress 2011 in Paris.

“Animal studies had suggested that inserting a balloon pump before opening the vessel would reduce the heart’s workload and, by doing so, could potentially reduce size,” Manesh Patel, MD, of the Duke Clinical Research Institute at Duke University, said in a press release. “However, having tested this observation in humans, we did not show similar results.”

IABC and SOC groups did not have significantly different mean infarct sizes. The percentage of left ventricle affected in the IABC group was 42.1% vs. 37.5% in the SOC group. Major bleeding or transfusion occurred in 3.1% of IABC patients and 1.7% of SOC patients by 30 days, and major vascular complications occurred in 4.3% of IABC patients and 1.1% of SOC patients. Death occurred by 6 months in 1.9% of IABC patients and 5.2% of SOC patients. Overall, not only did the study no meet its primary endpoint, it was also not powered to draw significant conclusions on clinical events.

“While this trial shows that the routine use of IABC cannot be recommended in STEMI, physicians should be vigilant about identifying those patients who are at risk for rapid deterioration and may benefit from counterpulsation,” Patel said.

For more information:

Disclosure: Dr. Patel reports no relevant financial disclosures.

PERSPECTIVE

Potential benefits of IABC are increase of coronary blood flow, increase of diastolic BP, increase of collateral circulation, increase of organ perfusion, decrease of afterload and increase of CI. [However,] IABC is not for all-comers with STEMI, and patients who might benefit from IABP still have to be defined.

Kurt Huber, MD
Department of Medicine, Cardiology and Emergency Medicine
Wilhelminen Hospital, Austria

Twitter Follow CardiologyToday.com on Twitter.

    See more from European Society of Cardiology Congress